US · BTAI · BIOTECHNOLOGY
BioXcel Therapeutics, Inc. (BTAI) intrinsic value and stock valuation
$0.07as of 2026-11-21 · Mkt cap 25.96M
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
BioXcel Therapeutics, Inc. DCF and intrinsic value
InvestorsCraft values BTAI with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from BTAI’s statements →
BioXcel Therapeutics, Inc. Graham Number
The Graham Number is not defined for negative earnings or book value. Guide · Calculator →
How the business is doing
Fiscal 2015–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
- PolyPid Ltd. (PYPD) $6.12
- Veru Inc. (VERU) $1.94
- Annovis Bio, Inc. (ANVS) $0.71
- Celularity Inc. (CELU) $0.46
- Evaxion Biotech A/S (EVAX) $2.25
- BioAtla, Inc. (BCAB) $1.74
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $640K | $2.27M | $1.38M | $380K | $0.00 |
| Operating income | -$-50.27M | -$-67.25M | -$-171.78M | -$-159.65M | -$-106.94M |
| Net income | -$-69.9M | -$-59.6M | -$-179.05M | -$-165.76M | -$-106.93M |
| EPSd | -$-5.72M | -$-23.46M | -$-98.38M | -$-94.72M | -$-64.81M |
| Operating cash flow | -$-57.62M | -$-72.03M | -$-155.01M | -$-135.34M | -$-82.15M |
| Capital expenditure | $0.00 | $0.00 | -$-20K | -$-140K | -$-450K |
| Free cash flow | -$-57.62M | -$-72.03M | -$-155.03M | -$-135.48M | -$-82.6M |
| Total assets | $44.9M | $38.3M | $73.7M | $205.9M | $239.4M |
| Total debt | $109.7M | $103M | $101.4M | $94.2M | $1.4M |
| Net debt | $81.2M | $73.1M | $36.2M | -$-99.57M | -$-231.57M |
| Total equity | -$-95.46M | -$-93.1M | -$-56.51M | $76.8M | $221.7M |
| Cash and short-term investments | $28.4M | $29.9M | $65.2M | $193.7M | $233M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $640K | $2.27M | $1.38M | $380K | $0.00 |
| Cost of revenue | $160K | $2.14M | $1.26M | $20K | $0.00 |
| Gross profit | $480K | $120K | $120K | $350K | $0.00 |
| Research and development expenses | $30.3M | $30.4M | $84.3M | $91.2M | $52.7M |
| Selling, general and administrative expenses | $20.5M | $34.5M | $83.4M | $68.8M | $54.2M |
| Other expenses | $0.00 | $2.44M | $4.16M | $0.00 | -$0.00 |
| Operating expenses | $50.7M | $67.4M | $171.9M | $160M | $106.9M |
| Cost and expenses | $50.9M | $69.5M | $173.2M | $160M | $106.9M |
| Interest income | $1.07M | $2.6M | $5.65M | $2.53M | $0.00 |
| Interest expense | $17M | $15.1M | $13.3M | $8.21M | $40K |
| Depreciation and amortization | $300K | $310K | $320K | $330K | $300K |
| Ebitda | -$-52.61M | -$-44.16M | -$-165.42M | -$-157.22M | -$-106.59M |
| Operating income | -$-50.27M | -$-67.25M | -$-171.78M | -$-159.65M | -$-106.94M |
| Total other income/expenses, net | -$-19.63M | $7.65M | -$-7.27M | -$-6.11M | $0.00 |
| Income before tax | -$-69.9M | -$-59.6M | -$-179.05M | -$-165.76M | -$-106.93M |
| Income tax expense | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | -$-69.9M | -$-59.6M | -$-179.05M | -$-165.76M | -$-106.93M |
| Weighted average shares outstanding | $12.2M | $2.54M | $1.82M | $1.75M | $1.65M |
| Weighted average diluted shares outstanding | $12.2M | $2.54M | $1.82M | $1.75M | $1.65M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $28.4M | $29.9M | $65.2M | $193.7M | $233M |
| Net receivables | $230K | $130K | $70K | $250K | $0.00 |
| Inventory | $720K | $680K | $1.99M | $1.99M | $0.00 |
| Total current assets | $44.7M | $37.4M | $72.1M | $202.9M | $236.8M |
| Property, plant and equipment, net | $230K | $860K | $1.47M | $2.06M | $2.54M |
| Goodwill and intangible assets | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Long-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current assets | $230K | $940K | $1.56M | $2.98M | $2.63M |
| Total assets | $44.9M | $38.3M | $73.7M | $205.9M | $239.4M |
| Accounts payable | $14.7M | $16M | $13.7M | $10.2M | $4.68M |
| Short-term debt | $25M | $370K | $350K | $320K | $290K |
| Deferred revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total current liabilities | $53.9M | $22.2M | $27.3M | $32.9M | $16.7M |
| Long-term debt | $84.7M | $102.6M | $101M | $93.8M | $1.1M |
| Deferred revenue, non-current | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current liabilities | $86.5M | $109.2M | $102.9M | $96.2M | $1.1M |
| Capital lease obligations | $70K | $440K | $790K | $1.1M | $1.4M |
| Total liabilities | $140.4M | $131.4M | $130.2M | $129.1M | $17.8M |
| Common stock | $80K | $50K | $30K | $30K | $30K |
| Retained earnings | -$-720.09M | -$-650.2M | -$-590.6M | -$-411.55M | -$-245.79M |
| Accumulated other comprehensive income (loss) | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total equity | -$-95.46M | -$-93.1M | -$-56.51M | $76.8M | $221.7M |
| Total investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $109.7M | $103M | $101.4M | $94.2M | $1.4M |
| Net debt | $81.2M | $73.1M | $36.2M | -$-99.57M | -$-231.57M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | -$-69.9M | -$-59.6M | -$-179.05M | -$-165.76M | -$-106.93M |
| Depreciation and amortization | $300K | $310K | $320K | $330K | $300K |
| Stock-based compensation | $2.77M | $6.16M | $18.6M | $17.3M | $19.5M |
| Change in working capital | -$-1.7M | -$-6.03M | $2.02M | $10.4M | $4.98M |
| Accounts receivable | -$-100K | -$-60K | $180K | -$-250K | $0.00 |
| Inventory | -$-40K | $1.31M | -$-10K | -$-1.99M | $0.00 |
| Accounts payable | $6.97M | -$-4.33M | -$-3.22M | $13M | $4.85M |
| Net cash provided by operating activities | -$-57.62M | -$-72.03M | -$-155.01M | -$-135.34M | -$-82.15M |
| Investments in property, plant and equipment | $0.00 | $0.00 | -$-20K | -$-140K | -$-450K |
| Acquisitions, net | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for investing activities | $0.00 | $0.00 | -$-20K | -$-140K | -$-450K |
| Common stock issued | $56.5M | $39.7M | $27M | $280K | $101M |
| Common stock repurchased | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | $56.5M | $36.7M | $26.5M | $96.2M | $102.5M |
| Net change in cash | -$-1.1M | -$-35.37M | -$-128.5M | -$-39.24M | $19.9M |
| Cash at end of period | $28.8M | $29.9M | $65.2M | $193.7M | $233M |
| Operating cash flow | -$-57.62M | -$-72.03M | -$-155.01M | -$-135.34M | -$-82.15M |
| Capital expenditure | $0.00 | $0.00 | -$-20K | -$-140K | -$-450K |
| Free cash flow | -$-57.62M | -$-72.03M | -$-155.03M | -$-135.48M | -$-82.6M |
Line items
Line items
Line items
About BioXcel Therapeutics, Inc.
BioXcel Therapeutics, Inc. is a biopharmaceutical firm that has reached the commercial phase, distinguishing itself by leveraging artificial intelligence to advance the creation of transformative therapies in the fields of neuroscience and immuno-oncology. Their distinctive methodology, termed 'drug re-innovation,' involves harnessing the power of big data and proprietary machine learning algorithms to uncover novel therapeutic applications for existing approved medications or drug candidates with established clinical validation. The company's flagship commercial offering, IGALMI (known during development as BXCL501), is a unique sublingual film delivering dexmedetomidine, designed for the rapid management of agitation experienced by adults with schizophrenia or bipolar I or II disorder. Beyond its current commercial use, BXCL501 is also undergoing further clinical investigation. Studies are underway to assess its efficacy for agitation in individuals with Alzheimer's disease, as an add-on therapy for major depressive disorder, and for use in community settings to address agitation linked to bipolar disorders and schizophrenia. Furthermore, BioXcel is advancing BXCL502, a candidate therapy targeting chronic agitation prevalent in dementia patients. Another key pipeline asset is BXCL701, an orally administered systemic innate immunity activator currently under investigation. This compound shows promise for treating aggressive prostate cancer and advanced solid tumors that have either become resistant to checkpoint inhibitors or have not yet received such treatment. Established in 2017, the company maintains its headquarters in New Haven, Connecticut.
- CEO
- Vimal D. Mehta
- Employees
- 29
- Beta
- 0.27
Explore
Frequently asked questions
What is the intrinsic value of BioXcel Therapeutics, Inc. (BTAI)?
InvestorsCraft does not currently publish an intrinsic value for BTAI. How the IC value is calculated.
Is BTAI undervalued?
InvestorsCraft does not publish an undervaluation signal for BTAI at this time.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.